Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritis, Juvenile Clear all
Completed Phase 3 Interventional Results available

Pediatric Arthritis Study of Certolizumab Pegol

NCT01550003
View directory record Official record
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
Certolizumab Pegol (CZP)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jun 10, 2026, 8:50 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

NCT01230827
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CNTO 148 (Golimumab), Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting No phase listed Observational

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

NCT02418442
View directory record Official record
Conditions
Rheumatic Joint Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 21 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT01455701
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 24 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

NCT03510442
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 4 Interventional

Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA

NCT00792233
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Withdrawal of anti-TNF therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jun 10, 2026, 8:50 PM EDT
Not yet recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yoga Therapy for Adolescents With Juvenile Idiopathic Arthritis

NCT03286933
View directory record Official record
Conditions
Adolescent Juvenile Idiopathic Arthritis, Yoga Therapy
Interventions
yoga
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

NCT01358383
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
naproxen, esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

NCT00642460
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

NCT01541917
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Web-based coping skills training, Online disease education
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Indianopolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 2 Interventional

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

NCT00000429
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Calcium carbonate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

NCT02296424
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions
ACZ885 150 mg (Canakinumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 20 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 2 Interventional

TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis

NCT00001862
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis, Uveitis
Interventions
Enbrel
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 8:50 PM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 4 Interventional Results available

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

NCT01563185
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
800 mg ibuprofen/26.6 mg famotidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
New Orleans, Louisiana • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Not applicable Interventional Results available

Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

NCT00487565
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Arthritis
Interventions
Total knee arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Early Phase 1 Interventional

Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis

NCT02052167
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
methotrexate prefilled pen
Device
Lead sponsor
medac GmbH
Industry
Eligibility
2 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jun 10, 2026, 8:50 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Of Tofacitinib In Pediatric JIA Population

NCT02592434
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 4 Interventional Results available

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

NCT00443430
View directory record Official record
Conditions
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions
methotrexate, methotrexate - etanercept - prednisolone arm
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Not applicable Interventional

Fitness Integrative Training for Pediatric Rheumatology Disorders

NCT06556992
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis
Interventions
FIT Teens
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jun 10, 2026, 8:50 PM EDT